Inside the Vial

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 2 mg once weekly to start, with changes every four weeks as needed. The listed sequence is 2 → 4 → 6 → 8 → 10 → 12 mg.

Timing and meals

Morning or evening, on the same day each week. The notes describe use with or without food.

Typical cycle

Ongoing weekly schedule.

For research reference only. These community notes are not treatment or dosing instructions. The published trial below used different escalation steps. Its timing information is listed separately.

TRIUMPH-1 · 80-week phase 3 obesity trial

Starting amount, changes and highest amount studied

Everyone assigned to retatrutide started at 2 mg. The researchers increased the amount at four-week intervals until each group reached its assigned target of 4 mg, 9 mg, or 12 mg.

Frequency and days per week

One injection under the skin per week.

Fasting and morning or evening

The sources below do not establish a preferred time of day or whether taking it with food makes a difference.

Study length, breaks and repeat cycles

The phase 3 trial ran for 80 weeks. The earlier phase 2 trial ran for 48 weeks. Neither tested a short repeating cycle.

The earlier phase 2 trial also included a separate group that stayed at 1 mg weekly. Phase 2 trial

TRIUMPH-1 phase 3 trial · 80-week study

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Interest centers on appetite, weight, and metabolic health. Retatrutide engages three receptors. GLP-1 and GIP are involved in nutrient and insulin signaling, while glucagon adds a pathway involved in energy and fuel regulation. Human trials test the net effect of engaging all three.

What researchers studied

GLP-1, GIP and glucagon receptor signaling in adults with obesity or overweight and a related condition.

What they found

In TRIUMPH-1, mean weight change at week 80 was −25.0% in the highest-dose arm and −3.9% with placebo. Gastrointestinal events were most common.

Published study methods

TRIUMPH-1 randomized 2,339 adults with obesity without diabetes to weekly study treatment or placebo for 80 weeks. TRIUMPH-2 separately enrolled adults with obesity and type 2 diabetes.

How to interpret the findings

TRIUMPH-1 also assessed knee pain and sleep apnea in prespecified subgroups and reported improvements on those measures. Those outcomes come from participants who had those conditions. The 80-week weight result is a group average from the trial.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 2.5 mg once weekly to start, with increases in 2.5 mg steps as needed after at least four weeks at the current dose. The listed sequence is 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg.

Timing and meals

Morning or evening, preferably on the same day each week, with or without food.

Typical cycle

Ongoing weekly schedule.

For research reference only. These community notes are not treatment or dosing instructions. See the separate European prescribing information below for the authorized Mounjaro formulation and its maintenance doses.

EMA product information for Mounjaro, the authorized formulation

Starting amount, changes and highest amount studied

2.5 mg is the starting dose. The prescriber moves to 5 mg after four weeks and decides whether later increases are needed. See the table below.

Frequency and days per week

One injection under the skin per week, preferably on the same day each week.

Fasting and morning or evening

Morning or evening, with or without food.

Study length, breaks and repeat cycles

The EMA describes weekly use and does not specify a repeating on/off cycle. SURMOUNT-1 studied 72 weeks in its main analysis.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

People look into tirzepatide for weight management and blood sugar. The dual GIP/GLP-1 action makes it relevant to studies of appetite, body weight, and glucose regulation. The evidence base includes distinct studies in people with and without type 2 diabetes.

What researchers studied

GIP and GLP-1 receptor signaling in type 2 diabetes and weight management.

What they found

In SURMOUNT-1, mean weight change at week 72 ranged from −15.0% to −20.9% across active arms versus −3.1% with placebo. The EMA evaluates Mounjaro for specific indications and formulations.

Published study methods

2,539 adults with obesity or overweight and a related condition, without diabetes, were randomized to weekly study treatment or placebo for 72 weeks.

How to interpret the findings

A longer SURMOUNT-1 analysis followed the subgroup with obesity and prediabetes. It found substantially less progression to type 2 diabetes during the trial in the tirzepatide groups. That finding applies to the subgroup enrolled and the treatment period studied.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 250–500 mcg (0.25–0.5 mg) per dose, usually 5–7 days per week, without a formal increase schedule.

Timing and meals

Morning and fasted are preferences reported in the community notes.

Typical cycle

8–12 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The published weight-loss trial below studied oral AOD-9604. The community injection schedule has not been established in controlled human trials.

24-week placebo-controlled trial in adults with obesity

Starting amount, changes and highest amount studied

Researchers compared three fixed amounts taken by mouth: 0.25 mg, 0.5 mg, and 1 mg. Participants stayed in their assigned group without a planned increase.

Frequency and days per week

Once a day by mouth in this trial. Two earlier human studies used injections into a vein. The published program did not test the community’s daily injections under the skin.

Fasting and morning or evening

The cited human evidence did not establish an advantage for morning or fasted use.

Study length, breaks and repeat cycles

The oral trial lasted 24 weeks. A human trial validating the community’s 8–12 week subcutaneous schedule was not identified.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

The idea was to isolate a small part of growth hormone and see whether it could influence fat metabolism without reproducing the effects of full-length growth hormone. That distinction is why the compound is discussed in weight and body-composition research.

What researchers studied

Weight change and fat metabolism.

What they found

A study with 536 participants with obesity found no significant weight loss compared with placebo.

Published study methods

Placebo-controlled human obesity research. The larger trial is summarized in the cited regulatory review.

How to interpret the findings

The published analysis of six trials focused on tolerability and found no detectable effect on serum IGF-1. That biochemical finding answers a different question from weight loss. The larger obesity trial did not establish a weight-loss benefit.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

2.5–5 mg total per day. The notes describe 2.5 mg as a common starting amount and 5 mg as a commonly discussed increase. Some community schedules split the daily total into two smaller amounts.

Timing and meals

Morning or earlier in the day is a common preference. The community notes do not specify a fasting requirement.

Typical cycle

8–12 weeks.

For research reference only. These community notes are not treatment or dosing instructions. Human dosing and safety have not been established in controlled trials.

Published animal research · mice with diet-induced obesity

Starting amount, changes and highest amount studied

The follow-up experiment compared fixed mouse doses of 10 and 32 mg per kg of body weight per day against a control. The 50 mg vial describes the package size. A human starting dose or titration schedule has not been established.

Frequency and days per week

Once a day by injection under the skin in this mouse experiment.

Fasting and morning or evening

Researchers gave the mouse injections late in the afternoon before the animals’ active period. A fasting period was used for a blood sugar test. These methods do not establish human timing or meal guidance.

Study length, breaks and repeat cycles

About four weeks in this mouse experiment.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

This small molecule is discussed in body-composition research because it blocks NNMT, an enzyme that uses nicotinamide and a methyl donor. Researchers are interested in whether changing that pathway alters how fat tissue handles energy.

What researchers studied

Inhibition of nicotinamide N-methyltransferase (NNMT) in obesity models.

What they found

Mouse studies reported improvements in selected body composition and metabolic measures. Human weight loss remains unestablished.

Published study methods

Researchers compared 5A1MQ with controls in diet-induced obesity in mice.

How to interpret the findings

The cited study examined body composition, metabolic measures, and liver pathology in diet-induced obesity. These readouts in mice support studying the pathway further. Human magnitude of effect, effective exposure, and durability have yet to be established.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 5–10 mg per dose. Some community schedules start at 5 mg and move to 10 mg without a formal titration plan. Common patterns in the notes are 2–3 days per week or five days on followed by two days off.

Timing and meals

Morning or before activity is a community preference. Some schedules use it fasted, while others do not.

Typical cycle

4–6 weeks.

For research reference only. These community notes are not treatment or dosing instructions. Some community protocols use SS-31 first and MOTS-c afterward. Think of the idea as tuning up the engine before putting it to work. Human trials have not established that this order improves results or validated the community schedule.

Lee et al. · High-fat diet study in mice

Starting amount, changes and highest amount studied

The eight-week experiment used a fixed amount of 0.5 mg per kg of mouse body weight. It did not test dose increases.

Frequency and days per week

The mice received MOTS-c once a day, seven days a week, by injection into the abdomen.

Fasting and morning or evening

The study did not compare morning with evening dosing or dosing with and without food.

Study length, breaks and repeat cycles

The main experiment lasted eight weeks. It did not test a break, a repeating cycle, or a human schedule.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

MOTS-c is of interest in exercise and metabolic research because mitochondria do more than make energy. They also send signals that influence how cells respond to stress. MOTS-c is one of the peptides studied in that signaling system.

What researchers studied

Mitochondrial signaling, insulin sensitivity and metabolic stress.

What they found

MOTS-c prevented diet-induced obesity and insulin resistance in mouse experiments. The findings apply to those models.

Published study methods

Controlled rodent experiments used diet and aging models and measured metabolic outcomes.

How to interpret the findings

The original mouse work examined insulin sensitivity and responses to a high-fat diet. Researchers have also measured naturally occurring MOTS-c around exercise in people. A change in an endogenous signal during exercise answers a different question from whether giving the peptide improves performance.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 100–200 mcg per dose, commonly one or two times daily, 5–7 days per week. Some community schedules start at 100 mcg and increase to 200 mcg without a formal titration plan.

Timing and meals

Near bedtime is a common preference. Some schedules also include a morning dose. The notes describe use away from food, often leaving a window before and after bedtime dosing.

Typical cycle

8–12 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The community describes this as a pulse-style schedule. The published human studies cited here used different compounds or the long-acting DAC version.

Published human evidence on related forms

Starting amount, changes and highest amount studied

The human studies cited used GHRH itself or long-acting CJC-1295 with DAC. They do not establish starting or target amounts for modified GRF 1–29.

Frequency and days per week

The cited studies do not establish a daily schedule for the No-DAC form.

Fasting and morning or evening

The Belgian study compared hormone responses at different sleep stages with GHRH itself. It did not test No-DAC bedtime dosing or meal timing.

Study length, breaks and repeat cycles

An 8–12 week course appears in the community notes above.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Short-acting growth hormone–releasing hormone analogues are discussed in connection with pituitary GH pulses. Recovery, sleep, and body composition are common reasons for interest, while a measured rise in a hormone is a separate outcome.

What researchers studied

Growth hormone–releasing hormone signaling.

What they found

The cited human trial observed sustained growth hormone and IGF-1 increases with the long-acting DAC form. Those results apply to that form.

Published study methods

The related study used randomized, placebo-controlled designs in healthy adults. A protocol for this exact form was not verified.

How to interpret the findings

DAC is the drug affinity complex that gives the published long-acting CJC-1295 its extended behavior. The cited DAC study cannot establish the duration, clinical benefit, or schedule of a short-acting catalog product. The exact sequence matters when matching a study.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 0.2–0.4 mg of the total blend per dose, commonly starting at 0.2 mg. Some schedules increase to 0.4 mg without a formal titration plan. The notes describe once daily as common, sometimes twice daily, on 5–7 days per week.

Timing and meals

Near bedtime is common. Some schedules include a morning dose. The notes describe use away from food, often with a fasting window around bedtime dosing.

Typical cycle

8–12 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The amounts refer to the combined blend. Controlled human studies have not established this schedule for the exact pairing.

Published human evidence on the individual compounds and related pairings

Starting amount, changes and highest amount studied

The human ipamorelin study tested it alone by IV. The human two-signal study used GHRH and GHRP-2.

Frequency and days per week

The cited studies measured short-term hormone responses.

Fasting and morning or evening

Bedtime and fasting preferences come from the community notes.

Study length, breaks and repeat cycles

The community notes describe an 8–12 week course. The cited human experiments did not test that course with the blend.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why researchers might study this blend

The pairing is based on two inputs to the pituitary: GHRH signaling and ghrelin receptor signaling. Researchers can ask whether engaging both changes the timing or amplitude of GH release.

What researchers studied

Two pathways involved in growth hormone release.

What they found

The cited papers examine individual agents or related forms. A clinical benefit for this exact blend remains unestablished.

Published study methods

A controlled protocol for the exact combination was not verified.

What the combination could add

The two cited sources examine different compounds, populations or models, and endpoints. They do not establish combined hormone effects, improvements in recovery or sleep, or clinical benefit from the blend.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 100–300 mcg per dose, with 100–200 mcg commonly discussed. Some schedules start around 100 mcg and adjust without a formal titration plan. The notes describe one or two doses per day, 5–7 days per week.

Timing and meals

Near bedtime is a common preference. Some schedules include a morning dose. The notes describe use away from food, often with a fasting window around bedtime dosing.

Typical cycle

8–12 weeks.

For research reference only. These community notes are not treatment or dosing instructions. Some community schedules pair it with CJC-1295 No DAC. The cited human growth hormone study used IV ipamorelin alone.

Gobburu et al. · Short-term growth hormone study in healthy male volunteers

Starting amount, changes and highest amount studied

Researchers compared five different weight-based amounts administered as 15-minute IV infusions.

Frequency and days per week

The study tracked the response to an IV infusion.

Fasting and morning or evening

Growth hormone peaked about 40 minutes after administration. Bedtime and meal timing were not studied.

Study length, breaks and repeat cycles

The study measured the short-term hormone response. The 8–12 week cycle comes from community notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Ipamorelin is discussed for its ability to stimulate GH release through the ghrelin receptor. Interest in gut motility comes from a separate function of that signaling pathway, which was tested in people after bowel surgery.

What researchers studied

Growth hormone release and postoperative bowel motility.

What they found

Danish experiments characterized selective growth hormone release. A later human trial found no statistically significant improvement in its primary measure of bowel recovery.

Published study methods

The clinical proof-of-concept trial randomized bowel surgery patients to intravenous study treatment or placebo.

How to interpret the findings

The Danish pharmacology work measured hormone responses in laboratory and animal systems. The clinical bowel study evaluated postoperative recovery and did not find a significant benefit on its primary endpoint. Neither design measured muscle gain or sleep quality.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 2 mg once daily, seven days per week, usually without titration.

Timing and meals

Near bedtime and away from food are common preferences in the notes. They emphasize a consistent schedule.

Typical cycle

12–26 weeks in the community notes. Human studies have also followed participants for longer.

For research reference only. These community notes are not treatment or dosing instructions. The original human trials used 2 mg daily. Bedtime and fasting are community preferences. Current prescription formulations use different labeled doses.

Published trials of the original formulation in adults with HIV

Starting amount, changes and highest amount studied

The original trials compared 2 mg once daily with placebo. Current US labels specify 1.4 mg daily for Egrifta SV and 1.28 mg daily for Egrifta WR. These prescriptions use different formulations.

Frequency and days per week

One injection under the skin each day in the published trials.

Fasting and morning or evening

The cited trials did not establish a benefit from bedtime or fasted dosing.

Study length, breaks and repeat cycles

26 weeks in the visceral-fat trial and 12 months in the liver-fat trial.

Egrifta SV prescribing information · Egrifta WR prescribing information

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Tesamorelin is studied for deep abdominal fat around the organs. As a GHRH analogue it acts through the GH and IGF-1 axis. The pivotal study measured visceral fat by CT, which gives more specific information than total weight.

What researchers studied

Visceral fat in adults with HIV and abdominal fat accumulation.

What they found

At 26 weeks, visceral fat measured by CT fell 15.2% with tesamorelin and rose 5.0% with placebo. This was a defined HIV population.

Published study methods

The double-blind study randomized adults receiving antiretroviral therapy to daily study treatment or placebo for 26 weeks.

How to interpret the findings

Another randomized study in people with HIV and fatty liver measured liver fat over 12 months and found a greater reduction with tesamorelin than with placebo. These studies involved defined HIV populations. They do not establish a benefit for general weight loss or bone density.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 200–500 mcg per dose, commonly starting at 200–300 mcg. Some schedules increase gradually within that range. Once daily, 5–7 days per week, is commonly discussed.

Timing and meals

Near bedtime is a common preference. The notes describe leaving a window away from food before bedtime dosing.

Typical cycle

8–12 weeks in the community notes. Some schedules run longer.

For research reference only. These community notes are not treatment or dosing instructions. The published studies below used different amounts and studied specific groups. The community fasting window and cycle are separate from those study designs.

Published studies of GHRH 1–29 in older men and in children with growth hormone deficiency

Starting amount, changes and highest amount studied

The older-adult study used a fixed 2 mg nightly dose. The pediatric study used 30 mcg per kg of body weight nightly.

Frequency and days per week

One injection under the skin each night in both studies.

Fasting and morning or evening

The pediatric study used bedtime dosing. The cited trials did not establish a fasting window.

Study length, breaks and repeat cycles

Six weeks in the older-adult study and up to one year in the pediatric study.

Geref International Study Group · Pediatric study

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Sermorelin is of interest because it uses the pituitary’s own GH release pathway. In children with GH deficiency, the meaningful outcome is growth velocity, measured over months.

What researchers studied

Growth hormone release in children with growth hormone deficiency.

What they found

The international study reported accelerated growth during the first year in children with growth hormone deficiency.

Published study methods

The study tracked growth velocity in children receiving daily GHRH therapy over a year.

How to interpret the findings

The cited study followed children during their first year of treatment. A change in pediatric growth velocity cannot answer adult questions about sleep, recovery, muscle gain, or aging.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 250–500 mcg per dose, with 250 mcg as a commonly discussed starting amount. Some schedules increase to 500 mcg. The notes describe once or twice daily, 5–7 days per week.

Timing and meals

Morning or evening, with flexible timing. The notes describe use with or without food.

Typical cycle

4–6 weeks in the community notes. Some schedules extend to eight weeks.

For research reference only. These community notes are not treatment or dosing instructions. The human knee report studied injections into the joint. It did not validate this community schedule for injections under the skin.

Published research · routes and study designs

Starting amount, changes and highest amount studied

The early knee report used injections directly into the joint. The ulcerative colitis trial used a rectal enema. A two-person safety pilot used IV infusions.

Frequency and days per week

These studies used different routes and designs for different questions.

Fasting and morning or evening

The human studies did not establish a preferred time of day or meal timing for injections under the skin.

Study length, breaks and repeat cycles

The ulcerative colitis trial ran for two weeks. The longer cycle above comes from the community notes.

Ulcerative colitis trial summary · Human IV safety pilot

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Interest in BPC-157 for soft-tissue recovery comes partly from Croatian experiments on tendons and ligaments. These models let investigators measure a defined injury and examine how tissue reconnects and handles mechanical stress.

What researchers studied

Tendon repair and tendon-cell activity.

What they found

Croatian researchers reported improved healing measures in transected rat Achilles tendons and growth of tendon cells in culture.

Published study methods

Surgically injured rats and cell cultures were studied. Human tendon recovery remains unestablished.

How to interpret the findings

In the Achilles study, researchers assessed surgically transected rat tendons and tendon-cell growth in culture. A separate Croatian study followed rat knee ligament healing through 90 days. Both provide preclinical evidence, with no demonstrated human tendon or ligament outcome in those studies.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 2–5 mg total per week, often split across two doses. Some schedules use a higher initial amount and then reduce frequency. There is no formal titration plan in the notes.

Timing and meals

Morning or evening, with flexible timing. The notes do not specify a fasting requirement.

Typical cycle

4–6 weeks initially in the community notes. Some schedules continue once weekly at a lower frequency.

For research reference only. These community notes are not treatment or dosing instructions. The published human wound study used a gel containing full-length thymosin beta-4. It did not test this injection schedule.

Published research on related thymosin beta-4 forms

Starting amount, changes and highest amount studied

The European human trial compared topical concentrations of full-length thymosin beta-4. It did not use the TB-500 fragment.

Frequency and days per week

The trial studied a gel applied to leg ulcers.

Fasting and morning or evening

The human gel study does not establish injection timing or meal timing.

Study length, breaks and repeat cycles

The human ulcer study followed healing over three months. The 4–6 week injection cycle comes from the community notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

TB-500 is discussed in repair research because a region of thymosin β4 interacts with actin, a protein involved in cell shape and movement. Cell movement is relevant when studying how cells enter and cover a wound.

What researchers studied

Actin-related cell movement and wound healing in preclinical models.

What they found

Fragment and full-length thymosin β4 studies are specific to the tested sequence and formulation. Product-specific human tissue repair benefit remains unestablished.

Published study methods

Philp et al. assessed dermal wound repair in diabetic and aged mice using full-length thymosin β4 and a synthetic actin-binding fragment.

How to interpret the findings

An Italian analytical study identified Ac-LKKTETQ in a sample sold as TB-500. The mouse wound study tested full-length thymosin β4 and a related synthetic fragment. Sequence and acetylation matter when connecting those results to a labeled product.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 0.5–1 mg of the total blend per dose, usually starting at 0.5 mg. Some schedules increase to 1 mg. Once daily, 5–7 days per week, is commonly discussed.

Timing and meals

Morning or evening, with flexible timing. The notes do not specify a fasting requirement.

Typical cycle

4–6 weeks. Some community schedules extend to eight weeks.

For research reference only. These community notes are not treatment or dosing instructions. The amounts refer to the combined 1:1 blend. The rat study used different amounts of the two compounds and a different injection route.

Biçer et al. · Published rat Achilles tendon study

Starting amount, changes and highest amount studied

The researchers compared each compound alone and both together. The combination used different amounts of BPC-157 and TB-500, unlike the 1:1 catalog blend.

Frequency and days per week

The rats received daily injections into the abdomen after surgery.

Fasting and morning or evening

The study did not compare time of day or fasting.

Study length, breaks and repeat cycles

Four weeks in the rat study.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why researchers might study this blend

The rationale pairs tendon and ligament models from BPC-157 research with work on cell movement and wound repair involving thymosin β4-related fragments. These are two different questions about repair biology.

What researchers studied

Tissue repair and cell movement.

What they found

A rat study tested both compounds together after Achilles tendon surgery.

Published study methods

The animal study compared each compound alone, the pairing, and an untreated control.

What the combination could add

The cited studies used different models and compounds separately. A study comparing the combination with each individual component would be needed to establish an added benefit.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 1–2 mg per injection, commonly starting at 1 mg once daily. Some schedules increase to 2 mg without formal titration. Daily and five days on followed by two days off are both discussed.

Timing and meals

Morning or evening. The notes describe evening as a preference for recovery-focused protocols and do not specify fasting.

Typical cycle

4–8 weeks in the community notes, with some longer schedules.

For research reference only. These community notes are not treatment or dosing instructions. These amounts describe the community’s subcutaneous protocol. Topical products are studied separately. The human studies cited below do not establish this injection schedule.

Published human research · topical gel and skin care

Starting amount, changes and highest amount studied

The diabetic ulcer study used a measured application of GHK-Cu gel as part of standard wound care.

Frequency and days per week

The study used daily topical applications.

Fasting and morning or evening

The topical study did not assess injection timing or meal timing.

Study length, breaks and repeat cycles

The post-laser skin study assessed outcomes at 12 weeks. The 4–8 week injection cycle comes from community notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Interest in GHK-Cu for skin and tissue remodeling comes from work on the extracellular matrix, the structural material that surrounds cells. Collagen production is one measurable part of that process.

What researchers studied

Collagen production and extracellular matrix remodeling.

What they found

A French laboratory study found increased collagen synthesis in fibroblast cultures. That outcome is specific to the cell model.

Published study methods

Cultured fibroblasts were exposed to GHK-Cu and assessed for collagen synthesis.

How to interpret the findings

French investigators measured collagen synthesis in fibroblast cultures and, in separate rat wound experiments, connective-tissue accumulation. These models support a rationale for studying matrix remodeling. They do not establish the effects of a specific cosmetic or injectable formulation in people.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 250–500 mcg per dose, commonly starting at 250 mcg. Some schedules increase to 500 mcg without formal titration. Once or twice daily, 5–7 days per week, is commonly discussed.

Timing and meals

Morning or evening, with flexible timing. The notes do not specify a fasting requirement.

Typical cycle

4–8 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The mouse colitis study used KPV in drinking water. The published evidence cited here does not establish the community’s subcutaneous schedule.

Dalmasso et al. · Published research in cells and mice

Starting amount, changes and highest amount studied

The cited work exposed lab-grown cells to KPV and gave KPV in drinking water to mice with colitis.

Frequency and days per week

KPV was given orally in the mouse experiments. The human colitis trial tested a different peptide, K(D)PT.

Fasting and morning or evening

The mouse study does not establish human injection or meal timing.

Study length, breaks and repeat cycles

The 4–8 week injection cycle comes from the community notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

KPV is studied for inflammatory signaling. The key gut finding concerns PepT1, a transporter that can take small peptides into cells. Researchers examined whether that uptake changes the inflammatory signals the cells produce.

What researchers studied

Intestinal inflammation and peptide transport through PepT1.

What they found

Researchers found reductions in inflammatory signaling in cell models and intestinal inflammation in mice.

Published study methods

Cell experiments and chemically induced colitis models in mice were used.

How to interpret the findings

The study measured signaling and cytokine responses in cell systems. It also assessed two chemically induced models of mouse colitis. The oral mouse experiments do not establish a clinical benefit for inflammatory bowel disease or other human gut conditions.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 1.75–3.5 mg of the total blend per dose, commonly starting at 1.75 mg. Some schedules increase to 3.5 mg. Once daily, five days on and two days off, is commonly discussed.

Timing and meals

Morning or evening. Evening is a community preference for recovery-focused protocols. The notes do not specify a fasting requirement.

Typical cycle

4–8 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The amounts refer to the full blend. The studies cited here tested individual compounds or related forms and did not establish this schedule for GLOW.

Published evidence on individual ingredients

Starting amount, changes and highest amount studied

The cited human wound study used topical GHK-Cu. The tendon and fragment studies used animal models.

Frequency and days per week

The cited studies did not test a daily injection schedule for the full blend.

Fasting and morning or evening

Morning, evening, and meal preferences come from the community notes.

Study length, breaks and repeat cycles

The 4–8 week cycle comes from the community notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why researchers might study this blend

GLOW brings together three research questions: how cells build collagen and other matrix material, how injured tendons and ligaments recover, and how cells move during wound repair. The interest comes from GHK-Cu, BPC-157, and thymosin β4-related research respectively.

What researchers studied

Collagen and tissue-repair pathways of individual ingredients.

What they found

The cited studies measured outcomes for individual compounds in fibroblasts or rat tendon models. A benefit for this exact blend remains unestablished.

Published study methods

A controlled protocol for the exact combination was not verified.

What the combination could add

The results below come from individual ingredients or related fragments in different models. Comparative studies of the full blend would be needed to tell whether these pathways work together or improve an outcome.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 2–4 mg of the total blend per dose, commonly starting at 2 mg. Some schedules increase to 4 mg without a formal titration plan. Once daily, five days on and two days off, is commonly discussed.

Timing and meals

Morning or evening. Evening is a community preference in inflammation- and recovery-focused protocols. The notes do not specify a fasting requirement.

Typical cycle

4–8 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The amounts refer to the full blend. The cited ingredient studies did not establish this injection schedule for KLOW.

Published evidence on individual ingredients

Starting amount, changes and highest amount studied

The cited KPV experiments used lab-grown cells and gave KPV in drinking water to mice. Separate studies tested GHK-Cu, BPC-157, and related thymosin fragments in other settings.

Frequency and days per week

The cited studies did not test a daily injection schedule for the full blend.

Fasting and morning or evening

Morning, evening, and meal preferences come from the community notes.

Study length, breaks and repeat cycles

The 4–8 week cycle comes from the community notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why researchers might study this blend

People look into KLOW for skin and connective-tissue repair and for its inflammation angle. The idea is to study different parts of a repair response together: inflammatory signaling, collagen and matrix formation, repair of injured tissue, and movement of cells into a wound. KPV adds the inflammation-focused line of research to the three ingredients in GLOW.

What researchers studied

Inflammatory signaling and tissue-remodeling pathways of individual ingredients.

What they found

The cited work includes mouse intestinal inflammation, fibroblast collagen and rat tendon models. A benefit for this exact blend remains unestablished.

Published study methods

A controlled protocol for the exact combination was not verified.

What the combination could add

The rationale is that the four ingredients address different processes relevant to repair. The studies used different tissues, species, formulations, and endpoints. A direct comparison of KLOW against its individual ingredients would be needed to show that the blend improves an outcome or that its ingredients act synergistically.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 5–10 mg once daily, seven days per week during the cycle. They describe choosing an amount and keeping it consistent rather than formally titrating.

Timing and meals

Near bedtime is commonly discussed. The notes do not specify a fasting requirement.

Typical cycle

10–20 days. The notes describe 5 mg daily for 20 days or 10 mg daily for 10 days.

For research reference only. These community notes are not treatment or dosing instructions. These notes describe injections under the skin. The published human body-clock study used a spray under the tongue and did not establish the injection schedule.

Ivko et al. · Published human body-clock marker study

Starting amount, changes and highest amount studied

The study used a spray under the tongue containing synthetic AEDG.

Frequency and days per week

Twice daily in the study.

Fasting and morning or evening

The study measured melatonin-related markers and did not establish a preferred bedtime injection or fasting schedule.

Study length, breaks and repeat cycles

20 days in the spray study.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Interest in Epithalon often comes from telomeres, the protective structures at chromosome ends, and telomerase, an enzyme that can extend them. Researchers can measure both in cells grown in a dish.

What researchers studied

Telomerase and cellular aging in cultured fibroblasts.

What they found

A Russian lab reported telomerase-related changes and extended proliferative potential in cultured cells. Human lifespan effects remain unestablished.

Published study methods

Researchers followed human fibroblasts in culture across repeated passages.

How to interpret the findings

The cited Russian study used human fibroblasts in culture and examined how long they continued dividing across passages. Cell division in that setting does not establish an effect on lifespan, sleep, or aging in people.

Community-reported schedule

Route

Subcutaneous (under the skin) or intramuscular (into a muscle), as described in the community notes.

Amount and frequency

The notes describe 25–100 mg per dose, commonly starting at 25–50 mg and increasing gradually. Two to five days per week and a five-days-on, two-days-off pattern are both discussed.

Timing and meals

Earlier in the day is a community preference. The notes do not specify a fasting requirement.

Typical cycle

4–8 weeks. Some schedules continue at a lower frequency.

For research reference only. These community notes are not treatment or dosing instructions. The notes also describe pairing NAD+ with SS-31 or MOTS-c. The published NAD+ infusion study used the IV route and did not test these injection schedules or pairings.

Grant et al. · Australian human metabolism pilot

Starting amount, changes and highest amount studied

The study used a single 750 mg intravenous infusion over six hours. It did not compare escalating doses.

Frequency and days per week

One infusion visit, not a weekly schedule.

Fasting and morning or evening

Participants fasted on the study day until after the final sample. That controlled the sampling conditions and did not compare fasting with eating.

Study length, breaks and repeat cycles

Six-hour infusion, with the final sample at eight hours. Repeated courses were not tested.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

NAD+ is central to redox reactions that help cells process fuel. It also serves as a substrate for enzymes involved in cellular stress responses and DNA repair. Those roles explain why it comes up in energy and aging research.

What researchers studied

NAD+ metabolism and changes in circulating metabolites.

What they found

An Australian pilot tracked changes in blood and urine metabolites. It measured biochemical handling rather than symptom or longevity outcomes.

Published study methods

Serial blood and urine samples were taken during and after a six-hour intravenous infusion.

How to interpret the findings

The Australian pilot measured how an infusion changed NAD-related molecules in blood and urine over hours. It did not test sustained changes in fatigue, cognition, or longevity. NAD+ itself and its oral precursors should be matched to their own studies.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 5–10 mg per dose, commonly once daily, 5–7 days per week. A 5 mg starting amount is commonly discussed. Some schedules increase to 10 mg without a formal titration plan.

Timing and meals

Morning or earlier in the day is a community preference. The notes do not specify a fasting requirement.

Typical cycle

4–6 weeks.

For research reference only. These community notes are not treatment or dosing instructions. Some community protocols put SS-31 before MOTS-c, with the idea of supporting energy production first. Human trials have not established that this sequence improves results.

TAZPOWER · Elamipretide in Barth syndrome

Starting amount, changes and highest amount studied

The randomized crossover used a fixed 40 mg study arm versus placebo.

Frequency and days per week

Once daily by subcutaneous injection during each treatment period.

Fasting and morning or evening

A preference for fasted or fed conditions, morning, or evening was not established by the cited evidence.

Study length, breaks and repeat cycles

Two 12-week crossover periods with a four-week washout between them. The washout separated trial periods. It was not tested as a beneficial break or annual cycle.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Elamipretide is studied because it interacts with cardiolipin, a lipid in the inner mitochondrial membrane. Researchers ask whether that interaction can help cells maintain energy production in specific mitochondrial disorders.

What researchers studied

Mitochondrial function and physical performance in Barth syndrome.

What they found

The randomized TAZPOWER phase did not meet its primary endpoints. Improvements in the open-label extension were observed without a concurrent placebo comparison.

Published study methods

Small randomized crossover trial in people with Barth syndrome, followed by an open-label extension.

How to interpret the findings

TAZPOWER measured walking distance and symptoms in Barth syndrome. In a separate 24-week trial in primary mitochondrial myopathy, elamipretide did not improve walking distance or fatigue compared with placebo. Both studies examined disease populations.

Community-reported schedule

Route

Intramuscular (into a muscle), as described in the community notes.

Amount and frequency

The notes describe 100–500 mg per dose, with 200–300 mg commonly discussed. Some schedules start lower and increase without a formal titration plan. Two to five days per week is common in the notes, and some describe daily use.

Timing and meals

Morning or evening, with flexible timing. The notes do not specify a fasting requirement.

Typical cycle

4–8 weeks. Some schedules continue longer at a lower frequency.

For research reference only. These community notes are not treatment or dosing instructions. The published intramuscular studies below used different amounts and studied specific medical conditions.

Published human research · intramuscular glutathione

Starting amount, changes and highest amount studied

The infertility trial compared 600 mg by intramuscular injection with placebo. An older fatty-liver study included a separate intramuscular group at 600 mg daily.

Frequency and days per week

Every other day in the infertility study and daily in the fatty-liver study.

Fasting and morning or evening

These studies did not establish a morning, evening, or fasting preference.

Study length, breaks and repeat cycles

Two months per treatment period in the infertility study and 30 days in the fatty-liver study.

Fatty-liver study · Intramuscular group details

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Glutathione helps cells manage oxidative stress. Human studies have measured antioxidant levels, immune markers, liver blood tests, skin pigmentation, and semen quality. The outcomes depend on the formulation, route, and people studied.

What researchers studied

Semen quality and liver blood tests.

What they found

A small Italian placebo-controlled trial found improvements in some semen measures.

Published study methods

Participants with specific causes of infertility received intramuscular glutathione or placebo and later switched treatments.

How to interpret the findings

The research overview identifies the route used in each study. The protocol sections focus on intramuscular injections. A result from an oral, topical, or combined regimen cannot establish the same effect for intramuscular injections alone.

Community-reported schedule

Route

Topical (applied to the skin or scalp).

Amount and frequency

The community notes describe 0.1–0.5% in topical formulations, commonly once or twice daily. They describe choosing a concentration and keeping it consistent.

Timing and meals

Morning, evening, or both. Fasting is not applicable to topical use.

Typical cycle

8–12 weeks in the community notes.

For research reference only. These community notes are not treatment or dosing instructions. The published AHK-Cu follicle study used concentrations measured in moles per liter in a lab culture. It did not test a 0.5% topical product or this schedule.

Pyo et al. · Published lab study using isolated human hair follicles

Starting amount, changes and highest amount studied

Researchers used 10⁻¹² to 10⁻⁹ mol/L in laboratory culture. This study did not test a percentage-strength topical product.

Frequency and days per week

The researchers exposed isolated follicles and cultured cells to AHK-Cu.

Fasting and morning or evening

The study did not compare morning and evening applications.

Study length, breaks and repeat cycles

The community’s 8–12 week topical schedule was not evaluated.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

AHK-Cu is discussed in scalp and hair research because dermal papilla cells help regulate activity at the base of a hair follicle. The South Korean researchers tested how the copper complex affected those cells and the follicles themselves.

What researchers studied

Hair follicle growth and dermal papilla cell activity.

What they found

South Korean researchers observed elongation of isolated human follicles and proliferation of cultured cells. Clinical scalp regrowth remains unestablished by this experiment.

Published study methods

Isolated follicles and dermal papilla cells were exposed to AHK-Cu in laboratory culture.

How to interpret the findings

Isolated follicles elongated and dermal papilla cells proliferated in the lab. Those readouts differ from scalp hair density, shedding, or visible regrowth in a controlled topical study.

Community-reported schedule

Route

Topical (applied to the skin).

Amount and frequency

The notes describe 5–10% as a cosmetic formulation range. This refers to the share of a diluted supplier ingredient in the finished product. The active peptide percentage depends on the supplier solution’s strength. Once or twice daily is commonly discussed.

Timing and meals

Morning, evening, or both. Fasting is not applicable to topical use.

Typical cycle

8–12 weeks before assessing visible changes is discussed in the community notes. Some routines continue longer.

For research reference only. These community notes are not treatment or dosing instructions. The published human patch study did not validate this concentration range or a home formulation from pure peptide powder.

Shin et al. · Human study of a multi-ingredient microneedle patch

Starting amount, changes and highest amount studied

The researchers tested a finished patch containing acetyl octapeptide-3 and other ingredients.

Frequency and days per week

The study used overnight patch applications around the eyes.

Fasting and morning or evening

The researchers studied overnight use of the patch.

Study length, breaks and repeat cycles

Researchers assessed the skin over 28 days.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

SNAP-8, or acetyl octapeptide-3, is discussed in cosmetics for the appearance of expression lines. The published human work here asks whether a finished patch changes the look and measured properties of skin near the eye.

What researchers studied

Cosmetic formulations and expression-line appearance.

What they found

A multi-ingredient patch improved some wrinkle and skin measurements. The contribution of acetyl octapeptide-3 on its own was not isolated.

Published study methods

A 24-person study compared an active microneedle patch with a hyaluronic acid patch on opposite sides of the face over 28 days.

How to interpret the findings

The active patch also contained other ingredients and used a microneedle delivery system. The study measured wrinkles, elasticity, and water loss over 28 days. The outcome applies to the tested patch as a whole.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 0.25–1 mg per dose, with 0.25–0.5 mg commonly discussed as a starting range. Some schedules increase toward 0.5–1 mg. The initial pattern is often daily, with some schedules reducing to one to three times a week afterward.

Timing and meals

Morning or evening, with flexible timing. The notes do not specify a fasting requirement.

Typical cycle

An initial one to three weeks, sometimes followed by less-frequent maintenance.

For research reference only. These community notes are not treatment or dosing instructions. These notes describe under-the-skin injections. Scenesse is a regulated implant with its own schedule. The cited studies do not establish the community maintenance schedule.

European and US EPP trials of the afamelanotide implant

Starting amount, changes and highest amount studied

Each active implant contained 16 mg of afamelanotide. No escalation was studied.

Frequency and days per week

One implant every 60 days. This schedule applied to the implant formulation used in the trials.

Fasting and morning or evening

The trials evaluated pain-free light exposure. They did not establish fasting or morning versus evening administration.

Study length, breaks and repeat cycles

Five implants in the European study over nine months and three in the US study over six months.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Afamelanotide stimulates a melanocortin pathway involved in pigmentation. The European clinical question was whether a regulated implant could increase pain-free light exposure in people with EPP, a condition that can cause severe pain after light exposure.

What researchers studied

Light tolerance in erythropoietic protoporphyria (EPP).

What they found

European and US trials found longer pain-free light exposure with afamelanotide implants. The EU assessment covers the specific Scenesse implant and EPP indication.

Published study methods

Two randomized placebo-controlled trials assessed pain-free light exposure over six to nine months.

How to interpret the findings

The trial outcome was time spent in light without pain, measured in a specific patient population. The EMA assessment concerns the implant, with its own formulation and release characteristics. The research does not establish the performance of other vial formulations.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 0.25–1 mg per dose, with 0.25–0.5 mg commonly discussed as a starting range. Some schedules increase toward 0.5–1 mg. The initial pattern is often daily, with some schedules reducing to one to three times a week afterward.

Timing and meals

Morning or evening, with flexible timing. The notes do not specify a fasting requirement.

Typical cycle

An initial one to three weeks, sometimes followed by less-frequent maintenance.

For research reference only. These community notes are not treatment or dosing instructions. The published pigmentation pilot used a short weight-based study schedule. It did not establish this community schedule or maintenance plan.

Dorr et al. · Early human pigmentation pilot

Starting amount, changes and highest amount studied

Researchers used weight-based amounts in three men and compared injections with saline.

Frequency and days per week

Weekday visits over two consecutive weeks, with Melanotan II and saline on alternating days.

Fasting and morning or evening

The study did not establish a preferred time of day, meal timing, or sun-exposure schedule.

Study length, breaks and repeat cycles

Two weeks in the pilot. The study did not test a maintenance cycle.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Interest comes from pigmentation and the observation that a compound acting at several melanocortin receptors can affect more than skin. Early investigators documented changes in pigmentation alongside other responses.

What researchers studied

Melanocortin receptor signaling and skin pigmentation.

What they found

A small phase 1 study reported pigmentation and observations including nausea and spontaneous erections. Its size and design limit conclusions.

Published study methods

Early dose-ranging clinical pilot assessed tolerability and pigmentation.

How to interpret the findings

This was an exploratory phase 1 pilot. It does not establish a dependable cosmetic tanning outcome, long-term skin effects, or a standard sun-exposure protocol.

Community-reported schedule

Route

Intranasal (through the nose) or subcutaneous (under the skin), as described in the community notes.

Amount and frequency

The notes describe 200–600 mcg per dose, commonly starting at 200–300 mcg. Some schedules increase gradually. One or two doses daily, 5–7 days per week, is commonly discussed.

Timing and meals

Morning is a community preference, with some schedules including an early-afternoon dose. The notes do not specify a fasting requirement.

Typical cycle

10–14 days. Some community schedules run 2–4 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The notes mention pairing Semax with Selank. The cited human imaging studies used nasal Semax and do not establish equivalent doses for injections or a combined schedule.

Lebedeva et al. · Published nasal Semax study in healthy adults

Starting amount, changes and highest amount studied

The imaging study compared 1% nasal Semax with placebo.

Frequency and days per week

A single administration for the imaging study.

Fasting and morning or evening

Researchers took MRI scans before treatment and at 5 and 20 minutes afterward.

Study length, breaks and repeat cycles

The imaging study tracked short-term brain activity. The community cycles come from separate notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Interest centers on neurological recovery and cognition. One Russian study looked at brain-derived neurotrophic factor (BDNF), a protein involved in how neurons respond to changes, during recovery after stroke.

What researchers studied

Rehabilitation and neurological outcomes after ischemic stroke.

What they found

A Russian clinical report examined neurological recovery and BDNF changes. Findings apply to the stroke population studied.

Published study methods

The cited study compared rehabilitation groups with and without adjunct Semax.

How to interpret the findings

The study evaluated Semax alongside rehabilitation and examined recovery measures and BDNF. Stroke rehabilitation findings cannot establish effects on focus, memory, or productivity in healthy adults.

Community-reported schedule

Route

Intranasal (through the nose) or subcutaneous (under the skin), as described in the community notes.

Amount and frequency

The notes describe 200–500 mcg per dose, with 250–300 mcg commonly discussed as a starting range. Some schedules increase gradually. One or two doses daily, 5–7 days per week, is commonly discussed.

Timing and meals

Morning or daytime is a common preference. Some schedules use it later in the day for winding down. The notes do not specify a fasting requirement.

Typical cycle

10–14 days. Some community schedules run 2–4 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The notes mention pairing Selank with Semax. The human imaging study tested them separately. The cited studies do not establish equivalent doses across routes or a combined schedule.

Published human research · anxiety comparisons and brain imaging

Starting amount, changes and highest amount studied

The anxiety studies compared Selank with other medications in people with diagnosed conditions. The brain-imaging study compared Selank, Semax, and placebo in separate groups.

Frequency and days per week

The brain-imaging study tracked the response after a single administration.

Fasting and morning or evening

Researchers took scans before treatment and at 5 and 20 minutes afterward. The study did not compare morning and evening or meal timing.

Study length, breaks and repeat cycles

The scan study measured short-term brain activity. The 10–14 day and longer schedules come from the community notes.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

People look into Selank mainly for anxiety and stress-related symptoms. The Russian clinical study compared the peptide with an active anxiety treatment in people with diagnosed conditions.

What researchers studied

Anxiety-related symptoms and stress pathways.

What they found

A small Russian comparative study reported changes in anxiety measures. Its findings are specific to the participants and design studied.

Published study methods

Participants with generalized anxiety disorder or neurasthenia were studied against an active comparator.

How to interpret the findings

The study reported changes in anxiety measures and also examined biological markers. This small comparison does not establish the size or reliability of an effect in everyday stress or healthy adults.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 100–300 mcg per dose, with 100–200 mcg commonly discussed as a starting range. Some schedules increase gradually. Once nightly, five to seven nights per week, is commonly discussed.

Timing and meals

The notes describe 30–60 minutes before bed and do not specify a fasting requirement.

Typical cycle

10–20 days. Some community schedules run two to four weeks.

For research reference only. These community notes are not treatment or dosing instructions. The community notes describe injections under the skin. The published Dutch sleep-lab study used IV DSIP and did not establish this bedtime injection schedule.

Bes et al. · Published Dutch sleep-lab study

Starting amount, changes and highest amount studied

The study compared weight-based IV DSIP with placebo in 16 people with chronic insomnia.

Frequency and days per week

One administration on each of three consecutive treatment days.

Fasting and morning or evening

Researchers gave the study treatment in the afternoon before overnight sleep testing.

Study length, breaks and repeat cycles

Five nights in the sleep lab, including three treatment nights.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

The name reflects early interest in sleep physiology. Researchers studied whether the peptide changes the timing, continuity, or structure of sleep in people with chronic insomnia.

What researchers studied

Sleep and waking patterns in chronic insomnia.

What they found

Early small studies explored sleep endpoints. A reliable clinical benefit remains unestablished.

Published study methods

A small human study evaluated 24-hour sleep–wake behavior in severe chronic insomnia.

How to interpret the findings

The human work was small and exploratory. Looking at 24-hour sleep–wake behavior differs from demonstrating a repeatable improvement in insomnia over weeks or months.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The notes describe 1.75 mg under the skin as needed, with no formal titration and no more than one dose in 24 hours.

Timing and meals

The community notes describe 45–60 minutes beforehand and do not specify a fasting requirement.

Typical cycle

Intermittent, as-needed use in the notes.

For research reference only. These community notes are not treatment or dosing instructions. The 1.75 mg figure matches the dose in the prescription Vyleesi label for its approved indication. The label also advises against more than eight doses per month.

RECONNECT trials and US prescribing information for Vyleesi

Starting amount, changes and highest amount studied

The phase 3 trials used 1.75 mg under the skin as needed. The Vyleesi label specifies this amount for the approved prescription product.

Frequency and days per week

The label says no more than one dose in 24 hours. More than eight doses per month is not recommended.

Fasting and morning or evening

The label says at least 45 minutes before anticipated sexual activity. The optimal timing window has not been fully established.

Study length, breaks and repeat cycles

The blinded trials lasted 24 weeks. The label calls for stopping after eight weeks if symptoms have not improved.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Bremelanotide is studied for sexual desire through central melanocortin signaling. The pivotal trials enrolled premenopausal women with acquired, generalized hypoactive sexual desire disorder.

What researchers studied

Sexual desire and related distress in a defined premenopausal population.

What they found

Two phase 3 trials reported improvements in desire and related distress versus placebo.

Published study methods

Two double-blind randomized trials compared study treatment with placebo over 24 weeks.

How to interpret the findings

The phase 3 studies found improvements in desire and related distress. They did not find a significant difference in the number of satisfying sexual events. Those are distinct outcomes and are worth reading separately.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe a fixed 1.6 mg per dose, usually twice weekly with no formal titration. More frequent schedules, including daily, depend on the research setting.

Timing and meals

Morning or evening, with no fasting requirement specified in the community notes.

Typical cycle

4–12 weeks in the community notes, sometimes longer.

For research reference only. These community notes are not treatment or dosing instructions. The published hepatitis B trial below used the same twice-weekly amount over a longer period. The community schedule is separate from the trial and has not been validated for autoimmune disease.

Chien et al. · Randomized chronic hepatitis B trial in Taiwan

Starting amount, changes and highest amount studied

Fixed 1.6 mg by subcutaneous injection.

Frequency and days per week

Twice weekly.

Fasting and morning or evening

The published abstract does not specify a time of day or meal timing.

Study length, breaks and repeat cycles

Two groups received treatment for 26 or 52 weeks.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Dendritic cells help decide what the immune system should respond to and pass that information to T cells. Researchers at the University of Perugia in Italy studied how TA-1 changes those signals, including signals involving regulatory T cells, which help keep immune responses in check.

What researchers studied

Immune regulation, antiviral responses and add-on cancer research.

What they found

An older Taiwan trial found a delayed improvement in certain hepatitis B markers after a 26-week course. An Italy-led melanoma study saw more tumor responses in two combination groups, with no clear survival benefit.

Published study methods

Condition-specific trials in people and separate lab and animal studies on immune signaling.

How to interpret the findings

In autoimmune disease, the immune system mistakenly targets the body’s own tissues. Italy-based studies of immune tolerance and an animal model of treatment-related gut inflammation help explain the interest in TA-1. These studies describe how the pathway might work. Clinical benefit for autoimmune disease remains unestablished.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 100–500 mcg per dose, often starting at 100–200 mcg, usually two or three times per week. Some schedules use gradual increases or more frequent dosing, with no formal titration schedule.

Timing and meals

Morning or evening, with no fasting requirement specified in the community notes.

Typical cycle

4–8 weeks in the community notes.

For research reference only. These community notes are not treatment or dosing instructions. The notes do not specify kisspeptin-10 or kisspeptin-54. The cited studies used a specified form and different schedules. They do not establish this community schedule for testosterone, libido or fertility.

Jayasena et al. · UK supervised IVF study of kisspeptin-54

Starting amount, changes and highest amount studied

Separate groups received one of four weight-based amounts from 1.6 to 12.8 nmol/kg under the skin. These were separate arms, with no within-person titration.

Frequency and days per week

One supervised administration as part of the IVF procedure.

Fasting and morning or evening

The injection was given in the evening after ultrasound confirmed follicle size. Timing was linked to the IVF treatment sequence.

Study length, breaks and repeat cycles

A single trigger during the study IVF cycle. The study did not test routine weekly or yearly use.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Kisspeptin starts a chain reaction. The brain releases GnRH, the pituitary releases LH, and LH signals the testes to make testosterone. Testosterone replacement therapy supplies testosterone directly. Kisspeptin is still being studied as a way to activate the body’s own signal.

What researchers studied

Testosterone signaling, sexual arousal and egg maturation.

What they found

UK researchers measured short-term hormone and arousal responses and studied a supervised trigger for egg maturation during IVF.

Published study methods

The studies used different forms, routes and participant groups.

How to interpret the findings

The testosterone rise was short term and came from a small IV study. Whether kisspeptin can offer sustained benefits for men with low testosterone or improve male fertility remains open. Sexual-response and IVF trials addressed separate questions.

Community-reported schedule

Route

Intramuscular (into a muscle) is the main route in these notes. Subcutaneous (under the skin) depends on the specific injectable product.

Amount and frequency

The community notes describe 0.5–1 mg per dose, with 1 mg a common reference point. They describe a fixed amount, usually one to three times weekly, sometimes more often initially.

Timing and meals

Morning is a community preference. The notes do not specify a fasting requirement.

Typical cycle

An initial 4–8 weeks in the community notes, sometimes followed by less frequent maintenance.

For research reference only. These community notes are not treatment or dosing instructions. The Spanish trial below studied diagnosed deficiency. The community schedule is separate. Clinical replacement schedules depend on the B12 form, the cause of deficiency and symptoms.

Spanish OB12 trial in older adults with diagnosed vitamin B12 deficiency

Starting amount, changes and highest amount studied

The study used 1 mg cyanocobalamin per administration. Its arms varied frequency and route.

Frequency and days per week

The oral arm used daily treatment through week 8, then weekly. The intramuscular arm used alternate days during weeks 1–2, weekly during weeks 3–8, then monthly.

Fasting and morning or evening

The trial report does not specify a time of day or fasting for injections.

Study length, breaks and repeat cycles

52 weeks of follow-up. The later, less frequent treatment was maintenance within the trial.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

B12 helps maintain myelin, the protective coating around nerves. It also helps the body process homocysteine, a substance made during normal metabolism. An injection bypasses absorption through the digestive tract, which can matter when the gut has trouble absorbing B12.

What researchers studied

Replacement in people with diagnosed vitamin B12 deficiency.

What they found

A Spanish primary-care trial found that both approaches normalized B12 in more than 90% of participants at week 8. The oral strategy did not meet the noninferiority criterion at one year.

Published study methods

Older adults were randomized to oral or intramuscular replacement and followed for a year.

How to interpret the findings

The Spanish OB12 trial measured whether B12 levels returned to normal in older adults with a deficiency. Its findings are about restoring B12 levels. UK guidance also recognizes fatigue and brain fog as possible symptoms of deficiency.

Community-reported schedule

Route

Intramuscular (into a muscle).

Amount and frequency

The community notes describe 0.5–1 mL, usually one to three times weekly. Some describe starting at 0.5 mL and moving to 1 mL. There is no formal titration schedule in the notes.

Timing and meals

Morning is a community preference. The notes do not specify a fasting requirement.

Typical cycle

6–12 weeks in the community notes, sometimes longer.

For research reference only. These community notes are not treatment or dosing instructions. The schedule is reported in milliliters. The listed ingredient amounts do not specify a reference volume, so they cannot be used to calculate milligrams per injection. The cited ingredient research does not establish this schedule for the full blend.

Evidence available for this profile

Starting amount, changes and highest amount studied

No verified human starting amount, titration, or maximum for this catalog form is summarized here.

Frequency and days per week

The exact intramuscular blend and community schedule are separate from the cited ingredient studies.

Fasting and morning or evening

A preference for fasted or fed conditions, morning, or evening was not established by the cited evidence.

Study length, breaks and repeat cycles

The cited evidence does not establish a repeat cycle, scheduled break, or number of cycles per year.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Lipotropic refers to how the body handles fats. Choline helps package fat so it can leave the liver, while carnitine helps move long-chain fats into mitochondria, where cells can use them as fuel.

What researchers studied

Fat transport, normal liver function, and how cells use fuel.

What they found

European research describes roles for individual ingredients, including choline and carnitine.

Published study methods

The exact intramuscular blend and community schedule are separate from the cited ingredient studies.

How to interpret the findings

The ingredient amounts below are listed as supplied. The formula notes did not specify a reference volume, so these amounts should not be read as concentrations or amounts per injection.

Community-reported schedule

Route

Subcutaneous (under the skin).

Amount and frequency

The community notes describe 2 mg once daily as a reference amount. Some list 2–5 mg daily. The notes generally describe a fixed amount with no formal titration.

Timing and meals

Morning or evening. The notes do not specify a fasting requirement.

Typical cycle

10–30 days in the community notes. Some describe longer courses of 8–12 weeks.

For research reference only. These community notes are not treatment or dosing instructions. The cited cell studies and patent observations do not validate this subcutaneous community schedule.

Evidence available for this profile

Starting amount, changes and highest amount studied

No verified human starting amount, titration, or maximum for this catalog form is summarized here.

Frequency and days per week

The published cell studies measured markers in cultures. Early patient observations were reported separately in a patent.

Fasting and morning or evening

A preference for fasted or fed conditions, morning, or evening was not established by the cited evidence.

Study length, breaks and repeat cycles

The cited evidence does not establish a repeat cycle, scheduled break, or number of cycles per year.

These details describe the study or authorized formulation cited. Study amounts are specific to the cited trial and are not personal dosing recommendations.

Why people are interested

Cartalax belongs to a group of short peptides associated with Russian researcher Vladimir Khavinson. The focus here is on chondrocytes, the cells that maintain cartilage, and the mesh of collagen and other materials they build around themselves. That mesh helps cartilage cushion a joint.

What researchers studied

Cartilage formation, cartilage-cell aging, and osteoarthritis research.

What they found

Two Russian lab studies reported changes in cartilage-related markers.

Published study methods

The published cell studies measured markers in cultures. Early patient observations were reported separately in a patent.

How to interpret the findings

AED is the three-amino-acid peptide. Some Russian papers also discuss Sigumir, a separate mixture extracted from animal tissue. The findings below identify which evidence concerns AED itself.